


## Bone Morphogenetic Protein 2/4 (BMP2/4)

**Catalogue no.:** Q36  
**Clone name:** 16C8-16C8  
**Product:** VHH directed against Bone Morphogenetic Protein 2 and 4 (BMP2/4)

**Target:** Bone Morphogenetic Proteins (BMPs) are TGF- $\beta$ -like secreted signaling molecules that play important roles in tissue homeostasis and diseases, such as cancer.<sup>1</sup> Although different, BMP2 (UniProtKB [P12643](#)) and BMP4 (UniProtKB [P12644](#)) originate from the same gene and show >80% sequence homology.<sup>2</sup> Both BMP2 and BMP4 preferentially bind to the type I BMP receptors, BMPR1A (Alk3) and BMPR1B (Alk6), but can also signal through ActRI (Alk2).<sup>3</sup>



Structure of BMP4A and B and the putative epitope of Q36 (C8, yellow), which prevents binding of BMP4 to BMPR1<sub>a</sub>.<sup>4</sup>

**Source:** Recombinant bivalent VHH (*Llama glama*), purified from *S.cerevisiae* using affinity chromatography. Immunization with recombinant BMP4.<sup>4</sup> Phage-display selection on immobilized BMP4 with total elution.<sup>4</sup>


**Specificity:** Human BMP2 and BMP4. Q36 binds to the 'wrist hydrophobic groove' on BMP4a, hereby preventing binding of BMP4 to its receptor BMPR1<sub>a</sub>.<sup>4,5</sup> Q35 and Q36 bind non-overlapping epitopes.

**Formulation:** 0.2  $\mu$ m filtered solution in PBS.

**Storage:** Shipped on blue ice. Store at 4°C or -20°C (aliquots). Addition of 0.02% sodiumazide is optional.

**Applications:** ELISA, Inhibition of signaling

### Examples:



Inhibition of BMP2- and 4-mediated activation of C2C12 cells by Q36 (C8C8) and Q36-mediated formation of intestinal organoids similar to those formed by treatment with BMP inhibitor Noggin.<sup>4</sup>

### Products:

Cat. No.	Target	Tag	Label
Q36	BMP2,4	Tagless	No label
Q36c	BMP2,4	C-direct	No label
Q36c-lab	BMP2,4	C-direct	Biotin / NOTA / HiLyte488 / IRDye800CW

### References:

- [Hogan, BL.](#), (1996) Genes Dev. 10:1580-1594
- [McCauley and Bronner-Fraser.](#) (2004) Evol Dev. 6:411-422
- [Miyazono et al.](#), (2005) Cytokine Growth Factor Rev. 16:251-263
- [Calpe et al.](#), (2015) Mol Cancer Ther 14:2527-40
- [Calpe et al.](#), (2016) MAbS 8:678-688